Search research articles
Contact Us
Filters
Showing results (81-90 of 215) with videos related to
Page
of 22
Sort By:
Cancer Chemotherapy and Pharmacology
|
September 12, 2025
RNA processing kinase inhibitors and epigenetic inhibitors in combination with oncology drugs or investigational agents in multi-cell type patient-derived tumor cell line spheroids
Beverly A Teicher, Thomas S Dexheimer, Thomas Silvers, et al.
Leukemia & Lymphoma
|
October 30, 2004
Oral valacyclovir as prophylaxis against herpes simplex virus reactivation during high dose chemotherapy for leukemia
Robert Z Orlowski, Sharon R Mills, Eric E Hartley, et al.
Plos One
|
August 22, 2015
Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies
Eric Laille, Tao Shi, Guillermo Garcia-Manero, et al.
Haematologica
|
January 3, 2012
Patient and physician characteristics associated with erythropoiesis-stimulating agent use in patients with myelodysplastic syndromes
Amy J Davidoff, Sheila Weiss Smith, Maria R Baer, et al.
British Journal of Haematology
|
March 7, 2012
Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure
Thomas Prébet, Steven D Gore, Sylvain Thépot, et al.
Leukemia Research
|
April 15, 2015
Variations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response
Vu H Duong, Maria R Baer, Franklin Hendrick, et al.
Blood Advances
|
August 2, 2022
Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea
Rong Wang, Rory M Shallis, Jessica M Stempel, et al.
Leukemia & Lymphoma
|
April 26, 2021
Clinical effectiveness of DNA methyltransferase inhibitors and lenalidomide in older patients with refractory anemia with ring sideroblasts: a population-based study in the United States
Xiaoyi Wang, Amer M Zeidan, Rong Wang, et al.
Blood Cancer Journal
|
June 13, 2018
Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?
Amer M Zeidan, Maximilian Stahl, Michelle DeVeaux, et al.
Blood
|
December 21, 2017
Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation
Amer M Zeidan, Maximilian Stahl, Xin Hu, et al.
Page
of 22
Search research articles
Search
Showing results (81-90 of 215) with videos related to
Sort By:
Page
of 22
Cancer Chemotherapy and Pharmacology
|
September 12, 2025
RNA processing kinase inhibitors and epigenetic inhibitors in combination with oncology drugs or investigational agents in multi-cell type patient-derived tumor cell line spheroids
Beverly A Teicher, Thomas S Dexheimer, Thomas Silvers, et al.
Leukemia & Lymphoma
|
October 30, 2004
Oral valacyclovir as prophylaxis against herpes simplex virus reactivation during high dose chemotherapy for leukemia
Robert Z Orlowski, Sharon R Mills, Eric E Hartley, et al.
Plos One
|
August 22, 2015
Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies
Eric Laille, Tao Shi, Guillermo Garcia-Manero, et al.
Haematologica
|
January 3, 2012
Patient and physician characteristics associated with erythropoiesis-stimulating agent use in patients with myelodysplastic syndromes
Amy J Davidoff, Sheila Weiss Smith, Maria R Baer, et al.
British Journal of Haematology
|
March 7, 2012
Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure
Thomas Prébet, Steven D Gore, Sylvain Thépot, et al.
Leukemia Research
|
April 15, 2015
Variations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response
Vu H Duong, Maria R Baer, Franklin Hendrick, et al.
Blood Advances
|
August 2, 2022
Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea
Rong Wang, Rory M Shallis, Jessica M Stempel, et al.
Leukemia & Lymphoma
|
April 26, 2021
Clinical effectiveness of DNA methyltransferase inhibitors and lenalidomide in older patients with refractory anemia with ring sideroblasts: a population-based study in the United States
Xiaoyi Wang, Amer M Zeidan, Rong Wang, et al.
Blood Cancer Journal
|
June 13, 2018
Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?
Amer M Zeidan, Maximilian Stahl, Michelle DeVeaux, et al.
Blood
|
December 21, 2017
Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation
Amer M Zeidan, Maximilian Stahl, Xin Hu, et al.
Page
of 22